Daniel Patterson
About Daniel Patterson
Daniel Patterson serves as the Vice President and Head of CMC, Biologics and Gene Therapies at Roivant Sciences, where he has worked since 2021. He has extensive experience in the pharmaceutical industry, having held various roles at GlaxoSmithKline and Cempra Pharmaceuticals.
Current Role at Roivant Sciences
Daniel Patterson serves as the Vice President and Head of CMC, Biologics and Gene Therapies at Roivant Sciences. He has held this position since 2021 and is based in the Raleigh-Durham-Chapel Hill Area. In this role, he oversees the chemistry, manufacturing, and controls aspects of biologics and gene therapies, contributing to the development and commercialization of innovative therapies.
Previous Experience at Roivant Sciences
Prior to his current role, Daniel Patterson worked at Roivant Sciences from 2018 to 2021 as the Head of CMC, Drug Substance. He also served as Senior Director of Pharmaceutical Development for a brief period in 2017-2018. His experience at Roivant Sciences spans multiple roles focused on advancing drug development processes.
Career at GlaxoSmithKline
Daniel Patterson has extensive experience at GlaxoSmithKline, where he held several positions from 2000 to 2015. He served as Principal Scientist in Chemical Development, Investigator in Chemical Development, and Senior Scientific Investigator in both API Chemistry and Analysis and 2nd Generation Product Development. His roles involved significant contributions to the development of pharmaceutical products.
Experience at Cempra Pharmaceuticals
From 2015 to 2017, Daniel Patterson was the Vice President of Chemistry, Manufacturing and Controls at Cempra Pharmaceuticals. In this role, he was responsible for overseeing the CMC functions, ensuring that the company's products met regulatory standards and quality requirements.
Education and Expertise
Daniel Patterson earned a Bachelor of Arts in Chemistry from Williams College, where he studied from 1991 to 1995. He later pursued a Ph.D. in Organic Chemistry at Stanford University, completing his studies from 1995 to 2000. His educational background provides a strong foundation for his expertise in chemistry and drug development.